. 2018 Jan 18;4(8):1106–1110. doi: 10.1001/jamaoncol.2017.4695

Table 2. Response Among Patients With and Without IDH-DS.

Patient Response	IDH-DS, No. (%) (n = 33)^a	No IDH-DS, No. (%) (n = 248)
Overall response^b	15 (45.5)	93 (37.5)
CR	6 (18.2)	49 (19.8)
CRi/CRp	6 (18.2)	16 (6.5)
PR	2 (6.1)	14 (5.7)
MLFS	1 (3.0)	14 (5.7)
Stable disease^c	16 (48.5)	121 (48.8)
Disease progression	1 (3.0)	14 (5.7)

Abbreviations: CR, complete remission; CRi, CR with incomplete hematologic recovery; CRp, CR with incomplete platelet recovery; IDH-DS, isocitrate dehydrogenase differentiation syndrome; MLFS, morphologic leukemia-free state; PR, partial remission; R/R AML, relapsed/refractory acute myeloid leukemia.

^{^a}

One patient was not evaluable for response; the patient developed IDH-DS on the ninth study day and discontinued treatment before a response assessment.

^{^b}

Investigator-reported overall response rate included CR, CRi/CRp, PR, or MLFS.

^{^c}

No international working group–defined response with no evidence of disease progression, sustained for 56 consecutive days.